APA (7th ed.) Citation

Yk, W., Gong, J., Sun, Y., Zhang, J., Ni, S., Hou, J., . . . Shen, L. (2023). Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors. Journal of clinical oncology, 41(4_suppl), 382. https://doi.org/10.1200/JCO.2023.41.4_suppl.382

Chicago Style (17th ed.) Citation

Yk, Wang, et al. "Interim Results of a First-in-human Phase 1 Study of Q-1802, a CLDN18.2/PD-L1 BsABs, in Patients with Relapsed or Refractory Solid Tumors." Journal of Clinical Oncology 41, no. 4_suppl (2023): 382. https://doi.org/10.1200/JCO.2023.41.4_suppl.382.

MLA (9th ed.) Citation

Yk, Wang, et al. "Interim Results of a First-in-human Phase 1 Study of Q-1802, a CLDN18.2/PD-L1 BsABs, in Patients with Relapsed or Refractory Solid Tumors." Journal of Clinical Oncology, vol. 41, no. 4_suppl, 2023, p. 382, https://doi.org/10.1200/JCO.2023.41.4_suppl.382.